Precigen Inc (FRA:I5X)
€ 0.8885 -0.041 (-4.41%) Market Cap: 262.21 Mil Enterprise Value: 250.39 Mil PE Ratio: 0 PB Ratio: 5.85 GF Score: 49/100

Precigen Inc R&D Day Transcript

Nov 04, 2021 / 03:00PM GMT
Release Date Price: €4.43 (-5.50%)
Steven Harasym
Precigen, Inc. - Head of IR

I would like to extend a special thanks to everyone joining us today for an update on our clinical programs and many of the exciting developments at Precigen.

Before we begin, I would like to remind you that during today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by our forward-looking statements. Please read the safe harbor statement contained in this presentation as well as risk factors contained in Precigen's most recent SEC filings for a more complete discussion of these risks and uncertainties.

I am pleased to be joined today by Dr. Helen Sabzevari, President and CEO of Precigen; Dr. David Sallman, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and the lead investigator for the PRGN-3006 study; Dr. Nora Disis, a Professor of Medicine

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot